Amerita Sets New Gold Standard for Immunoglobulin Therapy with First-in-Nation Accreditation

GREENWOOD VILLAGE, COLO. – March 12, 2026 – By Frank Reed

Amerita, a national provider of specialty infusion services, has established a new high-water mark for patient care by becoming the first infusion pharmacy in the United States to earn the Distinction in Immunoglobulin (Ig) Therapy Accreditation. The landmark achievement, awarded by the Accreditation Commission for Health Care (ACHC) in partnership with the Immunoglobulin National Society (IgNS), was granted after a comprehensive, multi-phase review that the company passed with zero deficiencies.

This pioneering accreditation validates Amerita's excellence in the delivery, management, and clinical oversight of immunoglobulin therapy—a critical treatment for patients with immunodeficiencies, autoimmune disorders, and other complex conditions. The achievement not only positions Amerita at the forefront of the specialty infusion industry but also sets a new, more rigorous benchmark for quality and safety that could reshape standards of care nationwide.

Raising the Bar on Clinical Excellence

The ACHC/IgNS Distinction in Ig Therapy is not a baseline certification. It was specifically designed to recognize elite providers that go beyond standard accreditation requirements. To even be eligible, an organization must already hold a foundational ACHC accreditation in either Specialty Pharmacy or Infusion Pharmacy. The distinction then adds a layer of intense scrutiny on the specific protocols and practices essential for high-quality Ig therapy.

The evaluation process is exhaustive, involving multiple checkpoints and an in-depth review of clinical competency, quality assurance measures, patient safety standards, and operational performance. The standards themselves are grounded in the IgNS Standards of Practice, an evidence-based framework developed by the only multidisciplinary organization dedicated solely to the field of Ig therapy.

Amerita’s role in this process was more than just that of an applicant. The company served as a field-testing site, participating in the development and validation of the very standards it would be measured against. This collaboration helped ensure the framework was both robust and relevant to real-world clinical practice.

“Amerita provided a field-testing site for ACHC’s Distinction in Ig Therapy. Through their participation, the standards were strengthened, and their relevance to the specialty confirmed,” said Caroline Girardeau, PharmD, MBA, ACHC’s Pharmacy Accreditation Program director. “Amerita has demonstrated a strong commitment to advancing the practice of Ig Therapy. Amerita’s patients can be confident in the safety and quality of the clinical services they receive from this organization, which is committed to achieving and delivering excellence.”

What 'Zero Deficiencies' Means for Patients

For the vulnerable patient populations who rely on immunoglobulin treatments, the language of accreditation can seem abstract. However, this distinction translates into tangible benefits that directly impact their health and well-being. Achieving the accreditation with zero deficiencies is a powerful testament to Amerita's clinical rigor and its unwavering focus on patient safety.

Immunoglobulin therapy is a complex biological treatment that requires meticulous management, from initial patient assessment and care planning to the precise administration of the infusion and ongoing monitoring. The new standards evaluate every step of this journey, ensuring ethical oversight and the use of data to continuously improve treatment effectiveness. This level of oversight is critical for optimizing patient outcomes and minimizing risks.

Luba Sobolevsky, PharmD, IgCP®, President and CEO of IgNS, emphasized the importance of this new standard. "The ACHC/IgNS Distinction in Ig Therapy represents the highest standard of care: an unwavering commitment to safety, efficacy, and optimal patient outcomes," she stated. "We are pleased to recognize Amerita for having met this rigorous standard of excellence in Ig therapy."

This commitment resonates deeply with patient advocacy groups like the Immune Deficiency Foundation (IDF) and the Jeffrey Modell Foundation, which have long championed the need for high-quality, accessible care for individuals with primary immunodeficiencies. For these patients, the assurance that their provider meets the industry’s highest possible standards can significantly enhance trust and peace of mind.

A Strategic Edge in a Competitive Market

Beyond the clinical accolades, this first-in-nation distinction provides Amerita, an affiliate of BrightSpring Health Services, with a significant strategic advantage in the rapidly growing specialty infusion market. The global home infusion therapy market is valued in the tens of billions of dollars and is projected to continue its expansion, driven by a shift away from costly hospital settings and a growing pipeline of infusible drugs.

In this competitive landscape, where providers like Option Care Health and Coram Specialty Infusion also offer comprehensive Ig therapy, differentiation is key. The ACHC/IgNS distinction serves as a powerful market differentiator, signaling to physicians, health systems, and payers that Amerita operates at a higher level of validated quality. This can be a decisive factor in securing referral partnerships and contracts.

Rich Denness, President of Amerita, framed the achievement in the context of the company's national growth strategy. “This accreditation represents far more than a milestone. It reflects who we are and the quality care standards we hold ourselves to every day,” he said. “As we continue to strengthen and grow the Amerita brand nationally, this distinction affirms our commitment to delivering the highest level of care, safety, and service to the patients and communities we are privileged to serve.”

This focus on quality aligns with the broader trend of patients preferring to receive care in their homes or at alternate infusion sites. By proving its ability to deliver hospital-level quality in these settings, Amerita is well-positioned to capture a larger share of this evolving market.

The Future of Infusion Therapy Standards

The introduction of the Ig Therapy Distinction and Amerita's pioneering achievement may signal a turning point for the entire specialty infusion industry. It establishes a clear pathway for providers to demonstrate specialized excellence and raises expectations for what constitutes high-quality care. As more providers seek to achieve this new benchmark—AOM Infusion was also noted as an early adopter—the overall quality of Ig therapy across the country is likely to improve.

This trend toward more granular, therapy-specific accreditations reflects the increasing complexity of modern medicine. As treatments become more sophisticated, general quality certifications may no longer be sufficient to guarantee expertise. The collaborative model used to develop these standards, involving both accrediting bodies and leading providers, could become a blueprint for elevating care in other specialized therapeutic areas.

For patients and providers alike, this move toward higher, more specific standards is a welcome development. It promises a future where quality is not just claimed but proven, leading to better outcomes, increased safety, and greater trust in the healthcare services that millions of Americans depend on.